Investors

    NASDAQ: STEM

      Listed on the NASDAQ Market since 1992, we are committed to       balancing our standards of scientific rigor and clinical integrity with our       corporate imperatives of value creation and long-term business       sustainability.

Corporate Profile

Driven by nearly 20 years of pioneering research and innovation, StemCells, Inc. is at the forefront of a breakthrough approach to treating human disease. We are applying our scientific and industry leadership in stem cell biology to discover, develop and commercialize novel therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery.
More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
CEO Podcast
10/15/2014  Martin McGlynn Interview on BioTech Nation Radio
Letter to Investors
May 2014  Letter to Investors from CEO Martin McGlynn
Recent News
10/07/14StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury
First Study Assessing Efficacy of Neural Stem Cells for the Treatment of Cervical Spinal Cord Injury NEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatmen... 
Printer Friendly Version
10/01/14StemCells, Inc. to Participate at the 2014 Stem Cell Meeting on the Mesa
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 4th Annual Partnering Forum, part of the 2014 Stem Cell Meeting on the Mesa, to be held October 7-9. Mr. McGlynn is scheduled to speak at 3:15 p.m. Pacific Time on Tuesday, October 7, at the Estancia La Jolla... 
Printer Friendly Version
09/04/14StemCells, Inc. to Participate at the 16th Annual Rodman & Renshaw Global Investment Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Sept. 4, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 16th Annual Rodman & Renshaw Global Investment Conference Wednesday, September 10, at 9:10 AM EDT in the Holmes II Salon room at the New York Palace Hotel, 455 Madison Avenue, New York, NY. Management is scheduled to present an update on the Company's programs, pipeline and ope... 
Printer Friendly Version
08/12/14StemCells, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
Conference Call to Be Hosted August 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the second quarter ended June 30, 2014. "The highlight for the quarter was the release of the first interim data from our ongoing... 
Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.18
Change (%) Stock is Up 0.02 (1.72%)
Volume227,508
Data as of 10/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet